$0.69
0.44% day before yesterday
Nasdaq, May 30, 10:12 pm CET
ISIN
US00688A1060
Symbol
ADIL
Sector
Industry

Adial Pharmaceuticals, Inc. Stock price

$0.69
-0.01 0.72% 1M
-0.39 35.98% 6M
-0.33 32.18% YTD
-0.77 52.76% 1Y
-31.07 97.84% 3Y
-38.19 98.24% 5Y
-100.57 99.32% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.00 0.44%
ISIN
US00688A1060
Symbol
ADIL
Sector
Industry

Key metrics

Market capitalization $5.41m
Enterprise Value $3.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.14
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.71m
Free Cash Flow (TTM) Free Cash Flow $-6.88m
Cash position $2.37m
EPS (TTM) EPS $-1.36
Short interest 4.65%
Show more

Is Adial Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Adial Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Adial Pharmaceuticals, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Adial Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Adial Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.18 5.18
1% 1%
-
- Research and Development Expense 3.52 3.52
159% 159%
-
-8.71 -8.71
35% 35%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8.71 -8.71
35% 35%
-
Net Profit -8.95 -8.95
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Adial Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adial Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
17 days ago
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2025.
Neutral
GlobeNewsWire
19 days ago
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market
Neutral
GlobeNewsWire
about one month ago
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Com...
More Adial Pharmaceuticals, Inc. News

Company Profile

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Head office United States
CEO Cary Claiborne
Employees 5
Founded 2010
Website www.adialpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today